Scarica l'app Stockscreener
15.71
0.95%
-0.15
Dopo l'orario di chiusura:
15.20
-0.51
-3.25%
Precedente Chiudi:
$15.86
Aprire:
$15.33
Volume 24 ore:
143.87K
Relative Volume:
2.56
Capitalizzazione di mercato:
$412.39M
Reddito:
$59,000
Utile/perdita netta:
$-21.81M
Rapporto P/E:
-1.4345
EPS:
-10.9518
Flusso di cassa netto:
$-18.07M
1 W Prestazione:
-2.84%
1M Prestazione:
+13.51%
6M Prestazione:
+4.39%
1 anno Prestazione:
+45.46%
Intervallo 1D:
$14.55
$15.83
Intervallo di 1 settimana:
$13.09
$16.68
Portata 52W:
$9.10
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Nome
Benitec Biopharma Inc
Settore
Industria
Telefono
(510) 780-0819
Indirizzo
3940 TRUST WAY, HAYWARD, CA
Confronta BNTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
15.71 | 416.33M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-16 | Iniziato | Oppenheimer | Outperform |
| 2024-09-12 | Iniziato | Guggenheim | Buy |
| 2024-07-22 | Iniziato | Leerink Partners | Outperform |
| 2024-06-13 | Iniziato | Piper Sandler | Overweight |
| 2020-10-05 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-02-26 | Downgrade | Maxim Group | Buy → Hold |
| 2015-12-31 | Reiterato | Maxim Group | Buy |
| 2015-09-16 | Reiterato | Maxim Group | Buy |
Mostra tutto
Benitec Biopharma Inc Borsa (BNTC) Ultime notizie
Pattern recognition hints at Benitec Biopharma Inc. upsideEarnings Growth Summary & Safe Capital Growth Plans - newser.com
Citizens raises Benitec BioPharma stock price target to $22 on strong BB-301 data - Investing.com Nigeria
Using economic indicators to assess Benitec Biopharma Inc. potentialInsider Selling & Consistent Profit Alerts - newser.com
Can Benitec Biopharma Inc. stock beat analyst upgrades2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Is Benitec Biopharma Inc. stock affected by interest rate hikesQuarterly Market Review & Precise Trade Entry Recommendations - newser.com
Is Benitec Biopharma Inc. a candidate for recovery play2025 Market Sentiment & Free Reliable Trade Execution Plans - newser.com
Benitec Biopharma appoints former Intra-Cellular CEO to board - Investing.com
Benitec Biopharma appoints former Intra-Cellular CEO to board By Investing.com - Investing.com South Africa
Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy - MSN
Is Benitec Biopharma Inc. stock positioned well for digital economyTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Custom strategy builders for tracking Benitec Biopharma Inc.Weekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Benitec Biopharma (BNTC) Announces Promising Phase 1b/2a Trial R - GuruFocus
Benitec Biopharma’s BB-301 Receives FDA Fast Track - TipRanks
Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug By Investing.com - Investing.com Nigeria
Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug - Investing.com Canada
Benitec Biopharma Appoints Dr. Sharon Mates to Board of Directors - TradingView
Benitec (NASDAQ: BNTC) reports 100% responders in Cohort; FDA Fast Track for BB-301 - Stock Titan
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire
Benitec Biopharma (NASDAQ: BNTC) appoints Sharon Mates; led ITI to $14.6B J&J deal - Stock Titan
Can Benitec Biopharma Inc. rally from current levels2025 Momentum Check & Free Community Supported Trade Ideas - newser.com
Strategies to average down on Benitec Biopharma Inc.July 2025 PreEarnings & Accurate Intraday Trade Tips - newser.com
Is Benitec Biopharma Inc. stock attractive for growth ETFsProfit Target & Technical Pattern Based Signals - newser.com
What sentiment indicators say about Benitec Biopharma Inc. stock2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Benitec Biopharma Inc. recovery potential after sell off2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Full Stock Market News from 2025-11-02 - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) to Share BB-301 OPMD Study Update in Investor Webcast - Stock Titan
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire Inc.
Benitec Biopharma Inc. stock trendline breakdownJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Chart based analysis of Benitec Biopharma Inc. trends2025 Institutional Moves & AI Powered Market Trend Analysis - newser.com
Is Benitec Biopharma Inc. stock attractive for long term wealth buildingJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - newser.com
Will HYGH stock return to pre crash levels2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Real time social sentiment graph for Benitec Biopharma Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Benitec Biopharma Inc Azioni (BNTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):